Disease · MONDO_0018746

mucous membrane pemphigoid

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mucous membrane pemphigoid. Diseases, record MONDO_0018746. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018746

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mucous membrane pemphigoid; Open Targets
Open Targets ID: MONDO_0018746; Open Targets
Other names: CP, MMP, Mucosynechial pemphigoid, benign mucous Membrane pemphigoid, cicatricial pemphigoid, cictricial pemphigoid with ocular involvement, mucosal pemphigoid, ocular pemphigoid, ocular pemphigus, vegetating cicatricial pemphigoid; Open Targets
Disease Ontology: DOID:11656; Disease Ontology
NCI Thesaurus: C34907; NCI Thesaurus
Orphanet: ORPHA:46486; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MYCOPHENOLIC ACID	CHEMBL866	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DAPSONE	CHEMBL1043	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	2	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3615	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 1/2	https://conductscience.org/library/genes/7124	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00584935	Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid	Phase 1/2	3	2011-04-21	Ocular Cicatricial Pemphigoid	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03295383	Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid	Phase 3	92		Severe Forms of Mucous Membrane Pemphigoid	CYCLOPHOSPHAMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02993133	Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.	Phase 3	53		Autoimmune Bullous Dermatose	MYCOPHENOLIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04744623	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Phase 2/3	10		Benign Mucous Membrane Pemphigoid	DAPSONE, MYCOPHENOLATE MOFETIL, PREDNISOLONE, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT02126020	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Phase 1/2	0		Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018746

GET https://conductscience.org/api/diseases/v1/MONDO_0018746/drugs

API reference For AI assistants